UNITED THERAPEUTICS Corp 8K

United Therapeutics Corporation appointed Victor Dzau, M.D., to its Board of Directors on July 22, 2026, as part of its board refreshment and strategic governance efforts.

On July 22, 2026, United Therapeutics Corporation, a public benefit corporation listed on Nasdaq under the ticker UTHR, appointed Victor Dzau, M.D., to its Board of Directors, adding a globally recognized physician-scientist and healthcare leader with prior roles including President of the National Academy of Medicine and senior leadership positions at Duke, Harvard, and Stanford. The company highlighted this move as part of an ongoing board refreshment effort intended to strengthen governance and support its public benefit mission focused on developing transplantable organs, organ alternatives, and groundbreaking treatments for rare diseases, with management expressing expectations that Dr. Dzau’s experience and insights will help guide strategic initiatives and transformation of patient care.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

8K

Source Type

fda

Accession

0001104659-26-086068

Alert Tier

5